Frequency Therapeutics, Inc.

Frequency Therapeutics, Inc. insiders are currently net sellers of FREQ stock, showing bearish sentiment over the past 90 days. Total sales of $18.6M outpace purchases of $5.3M, creating a net outflow of $13.2M. However, 100% of these sales are pre-scheduled 10b5-1 plan transactions.

Frequency Therapeutics, Inc. has 13 active insiders who have filed SEC Form 4 transactions in the past 90 days. David L. Lucchino (Executive) leads with 125 transactions totaling $11.8M. Christopher R. Loose (Executive) follows with 72 transactions worth $4.6M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Frequency Therapeutics, Inc.'s current score of 22/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Aug 21, 2023, when L. Lucchino David (Executive) disposed of 3,057 shares at $0.50 per share for $1.5K. This was executed under a 10b5-1 trading plan.

Based on SEC Form 4 filings from the past 90 days, FREQ insider trading sentiment is currently bearish with an Alignment Score of 22/100. The negative net flow of $13.2M shows more selling than buying. However, 100% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Frequency Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At FREQ, we track all Form 4 filings—currently showing 309 transactions from 13 insiders over 90 days.

A 10b5-1 plan allows Frequency Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At FREQ, approximately 100% of recent transactions are 10b5-1 trades. This high percentage suggests much of the selling is routine and pre-planned.

You can monitor Frequency Therapeutics, Inc. (FREQ) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 13 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Frequency Therapeutics, Inc.'s current score of 22/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $5.3M in purchases versus $18.6M in sales over 90 days, resulting in a net flow of -$13.2M.

SEC Form 4 filings are mandatory reports that Frequency Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At FREQ, the most common type is "S" with 50 occurrences. The most recent Form 4 was filed on Aug 21, 2023 by L. Lucchino David.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Frequency Therapeutics, Inc., approximately 100% of recent transactions are executed under 10b5-1 plans, while 0% appear to be discretionary trades. This high percentage suggests selling activity may be routine diversification.